<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>J&amp;J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned? — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">J&amp;J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?</h2>
    <div class="badge">2025-09-08T13:15:00+00:00</div>
    <ul>
      <li>AbbVie’s oncology segment generated combined revenues of $3.3 billion in the first half of 2025, up 4.2% year over year, as higher sales of Venclexta and contributions from new drugs, Elahere and Epkinly, more than offse</li>
<li>Stelara sales declined 38.6% in the first half of 2025.</li>
<li>It expects the Innovative Medicine business to grow 5% to 7% from 2025 to 2030.</li>
<li>The Zacks Consensus Estimate for J&amp;J’s 2025 sales and EPS implies a year-over-year increase of 5.2% and 8.8%, respectively.</li>
<li>Sales of its neuroscience drugs increased 20.3% to almost $5 billion in the first half of 2025, driven by higher sales of Botox Therapeutic, depression drug Vraylar and newer migraine drugs Ubrelvy and Qulipta.</li>
<li>Skyrizi and Rinvoq generated combined sales of $11.6 billion in the first half of 2025.</li>
<li>JNJ Estimate Movement Image Source: Zacks Investment Research The Zacks Consensus Estimate for AbbVie’s 2025 sales and EPS implies a year-over-year increase of 7.5% and 18.9%, respectively.</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=J%26J%20vs.%20AbbVie%3A%20Which%20Healthcare%20Powerhouse%20Is%20Better%20Positioned%3F%0A%E2%80%A2%20AbbVie%E2%80%99s%20oncology%20segment%20generated%20combined%20revenues%20of%20%243.3%20billion%20in%20the%20first%20half%20of%202025%2C%20up%204.2%25%20year%20over%20year%2C%20as%20higher%20sales%20of%20Venclexta%20and%20contributions%20from%20new%20drugs%2C%20Elahere%20and%20Epkinly%2C%20more%20than%20offse%0A%E2%80%A2%20Stelara%20sales%20declined%2038.6%25%20in%20the%20first%20half%20of%202025.%0A%E2%80%A2%20It%20expects%20the%20Innovative%20Medicine%20business%20to%20grow%205%25%20to%207%25%20from%202025%20to%202030.%0A%E2%80%A2%20The%20Zacks%20Consensus%20Estimate%20for%20J%26J%E2%80%99s%202025%20sales%20and%20EPS%20implies%20a%20year-over-year%20increase%20of%205.2%25%20and%208.8%25%2C%20respectively.%0A%E2%80%A2%20Sales%20of%20its%20neuroscience%20drugs%20increased%2020.3%25%20to%20almost%20%245%20billion%20in%20the%20first%20half%20of%202025%2C%20driven%20by%20higher%20sales%20of%20Botox%20Therapeutic%2C%20depression%20drug%20Vraylar%20and%20newer%20migraine%20drugs%20Ubrelvy%20and%20Qulipta.%0A%E2%80%A2%20Skyrizi%20and%20Rinvoq%20generated%20combined%20sales%20of%20%2411.6%20billion%20in%20the%20first%20half%20of%202025.%0A%E2%80%A2%20JNJ%20Estimate%20Movement%20Image%20Source%3A%20Zacks%20Investment%20Research%20The%20Zacks%20Consensus%20Estimate%20for%20AbbVie%E2%80%99s%202025%20sales%20and%20EPS%20implies%20a%20year-over-year%20increase%20of%207.5%25%20and%2018.9%25%2C%20respectively.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fj-j-vs-abbvie-which-healthcare-powerhouse-is-better-positioned%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/j-j-vs-abbvie-healthcare-131500100.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>